MDCX Medicus Pharma Ltd Forecast, Technical & Fundamental Analysis

MDCX in upward trend: 10-day moving average crossed above 50-day moving average on June 09, 2026

The 10-day moving average for MDCX crossed bullishly above the 50-day moving average on June 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 18, 2026. You may want to consider a long position or call options on MDCX as a result. In of 38 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

MDCX moved above its 50-day moving average on June 16, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where MDCX advanced for three days, in of 68 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 74 cases where MDCX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDCX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MDCX broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.011) is normal, around the industry mean (19.559). MDCX has a moderately low P/E Ratio (0.000) as compared to the industry average of (26.481). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.849). MDCX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). MDCX's P/S Ratio (0.000) is slightly lower than the industry average of (3.939).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MDCX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDCX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock worse than average.